BioSpace News Archive

Most people avoid networking connections due to uncomfortable situations. In contrast, strategic networking can be extremely beneficial for your career.

According to a recent BioSpace survey, 69% of employers indicated “finding quality talent” will be a significant challenge in 2019. Are you the quality talent life science employers are looking for? Don’t delay, apply now and show these employers you possess the quality skills they need!

Supporters and those opposed to the proposal are marshaling their forces ahead of the April 12 shareholder vote.

There are three companies looking for decisions by the U.S. Food and Drug Administration (FDA) this week. All three drugs are either resubmissions or have had to deal with various problems related to manufacturing or incomplete data. Here’s a look.

AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).

Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.

Gottlieb said the FDA believes there should be a premarket demonstration that a new opioid is superior to an already-approved opioid.

Cambridge, Mass.-based Sarepta Therapeutics announced data from its interim analysis of muscle biopsy endpoints of its therapy casimersen for Duchenne muscular dystrophy (DMD). The interim data was strong enough to support a probable New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) by mid-year.

Proteon Therapeutics, based in Waltham, Mass., announced that its PATENCY-2 Phase III clinical trial of vonapanitase in chronic kidney disease (CKD) failed to meet its co-primary endpoints.

The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.